Healthpeak Properties, Inc. reported fourth‑quarter 2025 results that included a diluted net income of $113.8 million, or $0.16 per share, and a diluted Funds From Operations (FFO) as adjusted of $0.47 per share. Revenue rose to $719.4 million, up 3.2 % from $698.0 million in the same quarter a year earlier, driven largely by robust performance in the outpatient medical and life‑plan segments. The company’s operating cash flow for the quarter was $1.20 billion, and diluted Adjusted Funds From Operations (AFFO) reached $284.1 million, or $0.40 per share.
The outpatient medical portfolio delivered a 4.4 % cash‑leasing spread and maintained a high occupancy rate, while the life‑plan segment posted a 16.7 % year‑over‑year and 15.4 % sequential increase in same‑store cash‑adjusted NOI, reflecting strong demand for senior‑care and outpatient services. In contrast, the lab segment experienced a modest 0.3 % decline in same‑store cash‑adjusted NOI, a result of a challenging life‑science funding environment and slower leasing activity in that space.
Management reiterated its 2026 outlook, guiding for diluted Nareit FFO per share and diluted FFO as adjusted of $1.70 – $1.74, a range that is slightly below analyst expectations but consistent with the company’s cautious stance. The guidance for same‑store NOI growth is 1 % to 1 %, a significant tightening from the 3.5 % target previously cited. The company also highlighted a $925 million capital‑recycling transaction that sold stabilized outpatient medical assets at 6.4 % cap rates, with an overall 2026 plan to recycle $1 billion of capital. In addition, Healthpeak completed the acquisition of a 1.4‑million‑square‑foot campus in South San Francisco for $600 million and sold a 239,000‑square‑foot lab campus in Salt Lake City for $68 million, further realigning its portfolio toward higher‑return life‑science and outpatient opportunities.
In a broader strategic context, Healthpeak is advancing the Janus Living IPO, a dedicated senior‑housing REIT, to unlock value and focus on its core life‑science and outpatient assets. The company’s leadership emphasized the importance of technology and automation, citing the appointment of a Head of Enterprise Innovation to drive operational efficiency. Management also noted that the life‑science market is approaching an inflection point, with improving M&A activity and limited new supply, positioning Healthpeak to capture upside as the sector recovers.
Investors reacted to the earnings release with a focus on the company’s forward guidance. While the quarter’s results beat expectations—particularly the $0.47 per share FFO as adjusted, which surpassed the consensus estimate of $0.45—the cautious 2026 outlook, especially the narrowed same‑store NOI growth target and the modest guidance range, tempered enthusiasm. The market’s attention to the guidance signals management’s concern about potential headwinds in the life‑science segment and a deliberate strategy to balance growth with risk management.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.